ARIA Associated with Aducanumab
Mar 23, 2022•3 min
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
Dr. Lon Schneider discusses the development of ARIA in Phase 3 EMERGE and ENGAGE trials that led to the FDA's accelerated approval of aducanumab for the treatment of MCI Alzheimer's disease.
Show references: https://www.alzforum.org/news/research-news/aduhelm-phase-3-data-aria-common-sometimes-serious
For the best experience, listen in Metacast app for iOS or Android